World's Best Scientists 2026 revealed!
Joseph D. Rosenblatt

Joseph D. Rosenblatt

D-Index & Metrics

Biology and Biochemistry

D-Index
62
Citations
17411
World Ranking
10623
National Ranking
4616

Joseph D. Rosenblatt publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Joseph D. Rosenblatt sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 245 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Joseph D. Rosenblatt D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Joseph D. Rosenblatt sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 62 D-Index — 46th percentile

46% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Joseph D. Rosenblatt is affiliated with the University of Miami in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a notable focus on Oncology, Pathology and Forensic Medicine, Molecular Biology, Immunology, and Cancer Research as subfields.

Their work covers multiple topics including Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Angiogenesis and VEGF in Cancer, Immune Cell Function and Interaction, Cancer, Hypoxia, and Metabolism, Biosimilars and Bioanalytical Methods, and Immunotherapy and Immune Responses.

Frequent collaborators in their research include Caron A. Jacobson, Alison R. Sehgal, Pashna N. Munshi, David G. Maloney, and Sven de Vos.

Joseph D. Rosenblatt has published extensively in several venues, most notably:

  • Blood (8 publications)
  • arXiv (Cornell University) (6 publications)
  • Cancer Research (5 publications)
  • Transplantation and Cellular Therapy (3 publications)
  • Cells (2 publications)

Representative recent papers authored or co-authored by Joseph D. Rosenblatt include:

  • Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial, 2021, The Lancet Oncology
  • Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL), 2020, Blood
  • Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5), 2023, Blood
  • Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases, 2021, Cells
  • 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL), 2022, Blood

Best Publications

  • Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Anas Younes;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

    Barbara Pro;Ranjana Advani;Pauline Brice;Nancy L. Bartlett

  • B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab

    R. John Looney;Jennifer H. Anolik;Debbie Campbell;Raymond E. Felgar

  • Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

    Judith E. Karp;Jeffrey E. Lancet;Scott H. Kaufmann;David W. End

  • High Rate of HTLV-II Infection in Seropositive IV Drug Abusers in New Orleans

    Helen Lee;Priscilla Swanson;Vernon S. Shorty;Jerome A. Zack

  • The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus

    Jennifer H. Anolik;Debbie Campbell;Raymond E. Felgar;Faith Young

  • A phase I dose-escalation trial of 2-deoxy- d -glucose alone or combined with docetaxel in patients with advanced solid tumors

    Luis E. Raez;Kyriakos Papadopoulos;Alejandro D. Ricart;E. Gabriella Chiorean

  • Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

    Robert Chen;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • The Role of Cyclic AMP in the Chemotactic Responsiveness and Spontaneous Motility of Rabbit Peritoneal Neutrophils The Inhibition of Neutrophil Movement and the Elevation of Cyclic AMP Levels by Catecholamines, Prostaglandins, Theophylline and Cholera Toxin

    Israel Rivkin;Joseph Rosenblatt;Elmer L. Becker

  • A second isolate of HTLV-II associated with atypical hairy-cell leukemia.

    Joseph D. Rosenblatt;David W. Golde;William Wachsman;Janis V. Giorgi

  • A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

    Andres Forero-Torres;John P. Leonard;Anas Younes;Joseph D. Rosenblatt

  • A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.

    Nancy L. Bartlett;Anas Younes;Matthew H. Carabasi;Andres Forero

  • Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

    Ajay K. Gopal;Robert Chen;Scott E. Smith;Stephen M. Ansell

  • Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

    Ranjana Advani;Andres Forero-Torres;Richard R. Furman;Joseph D. Rosenblatt

  • B cell regulation of the anti-tumor response and role in carcinogenesis

    Marc Schwartz;Yu Zhang;Joseph D. Rosenblatt

  • Increased rejection of primary tumors in mice lacking B cells: Inhibition of anti‐tumor CTL and TH1 cytokine responses by B cells

    Sangeeta Shah;Anagha A. Divekar;Shannon P. Hilchey;Hyun Mi Cho

  • A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

    Michelle A. Fanale;Andres Forero-Torres;Joseph D. Rosenblatt;Ranjana H. Advani

  • Identification of the gene responsible for human T-cell leukaemia virus transcriptional regulation

    Alan J. Cann;Joseph D. Rosenblatt;William Wachsman;Neil P. Shah

  • The x gene is essential for HTLV replication.

    Irvin S. Y. Chen;Dennis J. Slamon;Joseph D. Rosenblatt;Neil P. Shah

  • Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes.

    Ramila Philip;Elisa Brunette;Lydia Kilinski;Deepa Murugesh

Frequent Co-Authors

Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis
Irvin S. Y. Chen
Irvin S. Y. Chen University of California, Los Angeles
Howard J. Federoff
Howard J. Federoff University of California, Irvine
Ranjana H. Advani
Ranjana H. Advani Stanford University
Eckhard R. Podack
Eckhard R. Podack University of Miami
Joseph M. Connors
Joseph M. Connors University of British Columbia
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
Vicente Planelles
Vicente Planelles University of Utah
William J. Bowers
William J. Bowers University of Rochester
Andreas Engert
Andreas Engert University of Cologne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

There are many accessible pathways for students pursuing careers in biology, biochemistry, and related fields. For those seeking fast-track options, accelerated biology degree programs offer the opportunity to complete coursework more quickly, allowing graduates to enter the workforce or move on to advanced studies sooner.

Healthcare careers are also highly popular, with programs like online asn programs providing foundational training for aspiring nurses. These programs are designed to offer flexibility and prepare students to sit for the NCLEX-RN exam.

Another growing area is nutrition science, where students can gain expertise in food, health, and wellness through the best online nutrition degree options. These degrees can open doors to roles in research, clinical settings, or community health.

For those interested in healthcare leadership, cahme accredited online mha programs deliver essential managerial and organizational skills, helping graduates advance into high-demand healthcare administration positions.

Best Scientists Citing Joseph D. Rosenblatt

Trending Scientists

Recently Published Articles